Skip to main content

Table 3 Endpoints and outcomes

From: Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study

 

All patients

Conventional adaptation strategy

BLT-guided adaptation strategy

p

(n = 122)

(n = 61)

(n = 61)

 

Appropriate empirical antimicrobial therapy, % (n)

80% (98)

77% (47)

84% (51)

0.45

Early escalation, % (n)

7% (9)

0% (0)

15% (9)

<0.01*

Appropriate antimicrobial therapy after culture results, % (n)

88% (107)

77% (47)

98% (60)

<0.01

Delay before antimicrobial therapy escalation (h)

48 (28–60)

50.5 (48–73)

27 (24–28)

<0.01#

Optimal empirical antimicrobial therapy, % (n)

51% (62)

46% (28)

56% (34)

0.33

Early adaptation, % (n)

22% (27)

2% (1)

43% (26)

<0.01*

escalation

7% (9)

0% (0)

15% (9)

 

de-escalation

15% (18)

2% (1)

28% (17)

 

Optimal antimicrobial therapy after culture results, % (n)

71% (87)

48% (29)

95% (58)

<0.01

Delay before antimicrobial therapy adaptation (h)

49 (31.5–65)

58 (48–72)

28 (24.5–47)

<0.01#

Time to apyrexia (h)

24 (24–72)

24 (24–48)

30 (24–72)

0.19#

Time to leukocytosis <10.000/mm3 (days)

6 (3–13)

5 (3–12)

6 (3–15)

0.37#

Time to mechanical weaning (days)

5 (3–9)

4.5 (3–9)

5 (4–8)

0.51#

Length of ICU stay (days)

10 (5–16)

11 (6–17)

10 (5–15)

0.48

Mortality, % (n)

15% (18)

16% (10)

13% (8)

0.80

  1. BLT BetaLACTA® test
  2. *Fisher exact test was used due to multiple categorical variables
  3. #Wilcoxon test (non-paired) was used due to data not present for patients without antimicrobial escalation/adaptation, or for patients who had never been febrile, had hyperleukocytosis, nor been ventilated